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Endothelium-derived nitric oxide (NO) generated by
endothelial NO synthase (eNOS) is a key regulator of
endothelial function. Vascular NO induces vasodilation,
inhibits platelet aggregation and adhesion, prevents oxi-
dative modification of LDL cholesterol, limits vascular
smooth-muscle-cell proliferation, and decreases the
expression of proinflammatory genes that promote the
development of atherosclerosis. In the presence of cardiac
risk factors or cardiovascular disease, endothelial function
is impaired. A growing amount of evidence indicates that
oxidative stress – an imbalance between endogenous reac-
tive oxygen species (ROS) and antioxidants in favor of the
former – contributes markedly to endothelial dysfunc-
tion. A crucial aspect of endothelial dysfunction is the
reduced bioactivity of NO. A dominant mechanism reduc-
ing bioavailability of vascular NO relates to its rapid oxi-
dative inactivation by the ROS superoxide anion. In
addition, evidence indicates that persisting oxidative
stress renders eNOS dysfunctional, such that it ceases to
produce NO and produces superoxide instead. In recent
years, we have identified a number of compounds that
can revert these events and improve the bioavailability of
NO [1-3]. Below we describe the effects of trans-resvera-
trol as an example.
Trans-resveratrol, a naturally occurring phytoalexin found
in grapes and wine, is likely to contribute to the potential
of red wine in preventing human cardiovascular disease.
We have published previously, that resveratrol upregu-
lates eNOS expression and enhances eNOS activity [5,4]).
In addition to its (moderate) direct antioxidant effect, we
have found that resveratrol regulates gene expression of
pro- and antioxidative enzymes in the cardiovascular sys-
tem.
Resveratrol is an activator of sirtuin 1 (SIRT1) [6], a NAD+-
dependent histone deacetylase. SIRT1 facilitates the for-
mation of heterochromatin, the more tightly packed form
of chromatin associated with histone hypoacetylation and
gene repression. Multiple non-histone targets have also
been described for SIRT1. These include some transcrip-
tion factors or cofactors such as the tumor suppressor p53,
the forkhead box class O (FOXO) transcription factors,
nuclear factor κB (NF-κB), and peroxisome proliferator-
activated receptor-γ co-activator 1α (PGC-1α) [7]. Recent
studies point to SIRT1 as a key regulator of angiogenesis,
vascular tone and endothelial function.
Incubation of human umbilical vein endothelial cells
(HUVEC) and HUVEC-derived EA.hy 926 cells with res-
veratrol resulted in a concentration- and time-dependent
upregulation of superoxide dismutases (SOD)1, 2 and 3.
SIRT1 inhibition with sirtinol or knockdown of SIRT1 by
sRNAi markedly reduced the upregulation of SOD1 and 2
with little effect on SOD3. Also glutathione peroxidase 1
(GPx1) and catalase were upregulated by resveratrol. Sirti-
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nol and SIRT1 knockdown prevented the effect on GPx1,
but had no significant effect on the enhancement of cata-
lase. The same resveratrol regimen downregulated the
expression of NADPH oxidase Nox4, which occurred
independently of SIRT1. (6R)-5,6,7,8-tetrahydro-L-biopt-
erin (BH4) is an essential cofactor of eNOS. BH4 is sensi-
tive to oxidation and diminished in oxidative stress. BH4
is synthesized from guanosine 5'-triphosphate (GTP) via a
de novo pathway by the rate-limiting enzyme GTP
cyclohydrolase I (GCH1). Treatment of EA.hy 926 cells
with resveratrol enhanced the expression of GCH1, which
was reversed by sirtinol or knockdown of SIRT1 by siRNA.
Atherosclerotic apolipoprotein E knockout (ApoE-KO)
mice were treated with resveratrol (30 or 100 mg/kg/day
for 7 days via gavage). Resveratrol treatment significantly
reduced the levels of superoxide in the heart, which was
associated with an upregulation of SOD1-3, GPx1, and
catalase. In parallel, mRNA expression of NADPH oxidase
subunits Nox2 and Nox4 were reduced. Resveratrol also
inhibited the translocation of p47phox and Rac1 and
decreased the activity of the NADPH oxidase complex in
heart membrane fractions. The cardiac content of
malondialdehyde, an indicator of lipid peroxidation and
a biomarker for oxidative stress, was reduced by resvera-
trol treatment. Resveratrol also reduced 3-nitrotyrosine
levels in the heart. ApoE-KO mice are an animal model of
oxidative stress, and eNOS was found in an uncoupled
state, producing superoxide instead of NO. This was prob-
ably due to a relative deficiency of BH4. Treatment of
ApoE-KO mice with resveratrol enhanced the expression
of GCH1 and significantly increased BH4 levels in the
heart. This was associated with reduced superoxide pro-
duction by eNOS.
These data demonstrate that resveratrol protects against
vascular oxidative stress in vitro and in vivo, by changing
the expression pattern of pro- and antioxidative genes in
an advantageous manner. The data also indicate that
many of these effects are mediated by SIRT1, thereby iden-
tifying SIRT1 as a key regulator of cardiovascular oxidative
stress.
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